<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00909506</url>
  </required_header>
  <id_info>
    <org_study_id>adjuvant metformin for BC</org_study_id>
    <nct_id>NCT00909506</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Adjuvant Metformin for Operable Breast Cancer Patients</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seoul National University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Seoul National University Hospital</source>
  <brief_summary>
    <textblock>
      The investigators hypothesize that adjuvant metformin use in breast cancer patients with
      overweight or pre-diabetes mellitus (DM) may improve their body condition including weight
      loss.

      In this study, the investigators aim to test the efficacy and safety of adjuvant metformin
      for operable breast cancer patients with overweight or pre-DM.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2009</start_date>
  <completion_date type="Actual">December 2011</completion_date>
  <primary_completion_date type="Actual">March 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Weight loss</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">105</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Metformin 500 mg/d</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Metformin 500 mg/d</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Metformin 1000 mg/d</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Metformin 1000 mg/d</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Control: Receive placebo pill once every evening on 1~2 weeks.
Receive placebo pill in every morning and evening on 3~24 weeks (twice a day).</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin</intervention_name>
    <description>Metformin 500 mg/d: Receive oral metformin 500 mg dose once daily on 1~2 weeks.
Receive placebo pill in every morning and oral metformin 500 mg in every evening on 3~24 weeks.</description>
    <arm_group_label>Metformin 500 mg/d</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin</intervention_name>
    <description>Metformin 1000 mg/d : Receive oral metformin 500 mg dose once daily on 1~2 weeks. (Dose-escalate)
Receive oral metformin 500 mg in every morning and evening on 3~24 weeks (metformin 500 mg * twice a day = 1000 mg per day).</description>
    <arm_group_label>Metformin 1000 mg/d</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Operable Breast cancer patients with BMI ≥ 23 or 100 ≤ FBS &lt; 126

          -  From 6 month to 2 years since breast cancer operation and at least 4 weeks since
             chemotherapy or radiotherapy

          -  No drug use except Tamoxifen

          -  Normal OTPT &amp; Serum creatinine (&lt;=ULN)

          -  ECOG performance status 0-2 or Karnofsky PS 60-100%

          -  Life expectancy &gt; 12

          -  Absolute neutrophil count ≥ 1.5 x 10^9/L

          -  Platelets ≥ 100 x 10^9/L

          -  Pregnancy(-) &amp; without plan for pregnancy

          -  Sign a written informed consent form

        Exclusion Criteria:

          -  Type I or II DM or concurrent use of DM control agents

          -  Prior use of Metformin

          -  Hypoglycemia (FBS&lt; 70 with clinical symptom)

          -  Concurrent investigational or commercial agents

          -  Other diet or drug intervention for weight loss

          -  Concurrent use of steroid

          -  Abnormal liver and/or renal function

          -  Symptomatic congestive heart failure / Cardiac arrhythmia / Angina pectoris

          -  Ongoing or active infection

          -  lactic acidosis

          -  Pregnancy or ongoing breast feeding

          -  Anorexia, bulimia, nausea due to other disease for longer than 1 month

          -  Allergies or allergic reactions attributed to oral medications

          -  Inability to swallow or digest oral medications

          -  Physical or psychiatric illness that would limit compliance with study protocol

          -  Participants in other clinical trial
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Wonshik Han, M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of General Surgery, Seoul National University College of Medicine &amp; Seoul National University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>110-744</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>September 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 27, 2009</study_first_submitted>
  <study_first_submitted_qc>May 27, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 28, 2009</study_first_posted>
  <last_update_submitted>July 27, 2015</last_update_submitted>
  <last_update_submitted_qc>July 27, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 29, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metformin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

